Literature DB >> 8705761

Matrix remodelling in dilated cardiomyopathy entails the occurrence of oncofetal fibronectin molecular variants.

U Gabler1, A Berndt, H Kosmehl, U Mandel, L Zardi, S Müller, A Stelzner, D Katenkamp.   

Abstract

OBJECTIVES: To investigate whether disturbance of the cellular homoeostasis and integrity of cardiomyocytes in dilated cardiomyopathy (DCM) is accompanied by alterations in cell-matrix relations as indicated by changes in the deposition of fibronectin (FN) isoforms.
DESIGN: Tissue from a case series of patients with DCM was investigated by immunohistochemistry with antibodies against FN (all variants, clone IST4), ED-A+ FN (clone IST9), ED-B+ FN (clone BC1), and oncofetal glycosylated FN (clone 5C10). The sites of de novo synthesis of FN were demonstrated by means of non-radioactive RNA in situ hybridisation (ISH) with biotinylated FN cDNA fragments as the probe.
SETTING: University hospital. PATIENTS: Samples from 10 patients with clinical criteria and histological diagnosis of DCM and from 3 individuals with normal hearts.
INTERVENTIONS: Samples were obtained by right ventricular endomyocardial biopsy. MAIN OUTCOME MEASURE: Distribution of oncofetal FN variants in DCM hearts.
RESULTS: Immunostaining of FN (IST4, all variants) showed a coarse interstitial network in normal and diseased myocardium. ED-A+ FN was deposited as fine interstitial spots in normal myocardium and in DCM samples. Immunostaining for oncofetal glycosylated FN and ED-B+ FN was not seen in normal adult myocardium, whereas myocardium from DCM patients showed focal and delicate staining in the interstitium. RNA ISH showed that these deposits resulted from local FN synthesis.
CONCLUSION: The results accord with de novo expression of oncofetal FN variants in hearts from patients with DCM. The oncofetal FN variants may serve as disease markers in myocardium affected by DCM.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8705761      PMCID: PMC484310          DOI: 10.1136/hrt.75.4.358

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  40 in total

Review 1.  The challenge of cardiomyopathy.

Authors:  W H Abelmann; B H Lorell
Journal:  J Am Coll Cardiol       Date:  1989-05       Impact factor: 24.094

2.  The oncofetal structure of human fibronectin defined by monoclonal antibody FDC-6. Unique structural requirement for the antigenic specificity provided by a glycosylhexapeptide.

Authors:  H Matsuura; K Takio; K Titani; T Greene; S B Levery; M E Salyan; S Hakomori
Journal:  J Biol Chem       Date:  1988-03-05       Impact factor: 5.157

3.  Participance of fibronectin and various collagen types in the formation of fibrous extracellular matrix in cardiosclerosis.

Authors:  B V Shekhonin; S P Domogatsky; G L Idelson; V E Koteliansky
Journal:  J Mol Cell Cardiol       Date:  1988-06       Impact factor: 5.000

4.  Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients.

Authors:  W C Roberts; R J Siegel; B M McManus
Journal:  Am J Cardiol       Date:  1987-12-01       Impact factor: 2.778

5.  The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma.

Authors:  H Matsuura; S Hakomori
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

6.  Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene.

Authors:  A R Kornblihtt; K Umezawa; K Vibe-Pedersen; F E Baralle
Journal:  EMBO J       Date:  1985-07       Impact factor: 11.598

7.  Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon.

Authors:  L Zardi; B Carnemolla; A Siri; T E Petersen; G Paolella; G Sebastio; F E Baralle
Journal:  EMBO J       Date:  1987-08       Impact factor: 11.598

8.  Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells.

Authors:  L Borsi; B Carnemolla; P Castellani; C Rosellini; D Vecchio; G Allemanni; S E Chang; J Taylor-Papadimitriou; H Pande; L Zardi
Journal:  J Cell Biol       Date:  1987-03       Impact factor: 10.539

9.  Differential expression of the ED sequence-containing form of cellular fibronectin in embryonic and adult human tissues.

Authors:  T Vartio; L Laitinen; O Närvänen; M Cutolo; L E Thornell; L Zardi; I Virtanen
Journal:  J Cell Sci       Date:  1987-11       Impact factor: 5.285

10.  A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors.

Authors:  B Carnemolla; E Balza; A Siri; L Zardi; M R Nicotra; A Bigotti; P G Natali
Journal:  J Cell Biol       Date:  1989-03       Impact factor: 10.539

View more
  11 in total

1.  Extracellular matrix alterations in cardiomyopathy: The possible crucial role in the dilative form.

Authors:  V I Kapelko
Journal:  Exp Clin Cardiol       Date:  2001

Review 2.  Histochemistry and cell biology: the annual review 2010.

Authors:  Stefan Hübner; Athina Efthymiadis
Journal:  Histochem Cell Biol       Date:  2011-01-29       Impact factor: 4.304

Review 3.  Tenascin-C in cardiovascular remodeling: potential impact for diagnosis, prognosis estimation and targeted therapy.

Authors:  Marcus Franz; Christian Jung; Alexander Lauten; Hans R Figulla; Alexander Berndt
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

4.  Differential modes of regulation of interleukin-1beta expression by extracellular matrices.

Authors:  J Roman; J D Ritzenthaler; R L Perez; S L Roser
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

5.  Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies.

Authors:  Marcus Franz; Bernhard R Brehm; Petra Richter; Katja Gruen; Dario Neri; Hartwig Kosmehl; Khosro Hekmat; Andre Renner; Jan Gummert; Hans R Figulla; Alexander Berndt
Journal:  J Mol Histol       Date:  2010-03-16       Impact factor: 2.611

6.  De novo expression of fetal ED-A(+) fibronectin and B (+) tenascin-C splicing variants in human cardiac allografts: potential impact for targeted therapy of rejection.

Authors:  Marcus Franz; Monika Matusiak-Brückner; Petra Richter; Katja Grün; Barbara Ziffels; Dario Neri; Hansjörg Maschek; Uwe Schulz; Alexander Pfeil; Christian Jung; Hans R Figulla; Jan Gummert; Alexander Berndt; André Renner
Journal:  J Mol Histol       Date:  2014-05-03       Impact factor: 2.611

Review 7.  Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects.

Authors:  H Kosmehl; A Berndt; D Katenkamp
Journal:  Virchows Arch       Date:  1996-12       Impact factor: 4.064

8.  Extra cellular matrix remodelling after heterotopic rat heart transplantation: gene expression profiling and involvement of ED-A+ fibronectin, alpha-smooth muscle actin and B+ tenascin-C in chronic cardiac allograft rejection.

Authors:  Marcus Franz; K Grün; P Richter; B R Brehm; M Fritzenwanger; K Hekmat; D Neri; J Gummert; H R Figulla; H Kosmehl; A Berndt; A Renner
Journal:  Histochem Cell Biol       Date:  2010-10-08       Impact factor: 4.304

9.  Comparative analysis of oncofetal fibronectin and tenascin-C expression in right atrial auricular and left ventricular human cardiac tissue from patients with coronary artery disease and aortic valve stenosis.

Authors:  Anja Baldinger; Bernhard R Brehm; Petra Richter; Torsten Bossert; Katja Gruen; Khosro Hekmat; Hartwig Kosmehl; Dario Neri; Hans-Reiner Figulla; Alexander Berndt; Marcus Franz
Journal:  Histochem Cell Biol       Date:  2011-04-10       Impact factor: 4.304

Review 10.  Fibroblast contributions to ischemic cardiac remodeling.

Authors:  Ryan M Burke; Kimberly N Burgos Villar; Eric M Small
Journal:  Cell Signal       Date:  2020-11-02       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.